Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Coccidioidomycosis - Overview
Coccidioidomycosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Coccidioidomycosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Coccidioidomycosis - Companies Involved in Therapeutics Development
Acea Biotech Inc
Amplyx Pharmaceuticals Inc
F2G Ltd
Mycovia Pharmaceuticals Inc
Scynexis Inc
Valley Fever Solutions Inc
Coccidioidomycosis - Drug Profiles
Amphotericin B sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
coccidioidomycosis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fosmanogepix - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ibrexafungerp citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nikkomycin Z - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
olorofim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
otesecozole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VT-1598 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Coccidioidomycosis - Dormant Projects
Coccidioidomycosis - Product Development Milestones
Featured News & Press Releases
Oct 24, 2019: SCYNEXIS expands FURI protocol to a broader range of refractory serious fungal infections, building on Ibrexafungerp’s positive data and favorable toxicology profile observed to date
Sep 09, 2019: FDA grants Fast Track Status to Amplyx Pharmaceuticals for IV and Oral Formulations of Fosmanogepix (APX001) for seven different indications
Jun 07, 2018: Amplyx Announces Presentations on APX001 at American Society for Microbiology Microbe 2018 and the 20th Symposium on Infections in the Immunocompromised Host
Jul 13, 2017: FDA Grants Fast Track Desigtion to VT-1598 for Treatment of Valley Fever
May 17, 2017: Viamet To Present Data on VT-1598 at The American Society for Microbiology’s ASM Microbe 2017 Conference
Nov 16, 2016: FDA Grants Orphan Drug Desigtion to Amplyx Pharmaceuticals for APX001 for Treatment of Multiple Invasive Fungal and Mold Infections
Sep 15, 2016: FDA Grants QIDP Desigtion to VT-1598 for Treatment of Valley Fever
Jun 14, 2016: Amplyx Pharmaceuticals Announces Qualified Infectious Disease Product Desigtion for APX001 in Three Life-threatening Fungal Infections
May 25, 2016: Viamet Receives Orphan Drug Desigtion from the FDA for VT-1598 for the Treatment of Coccidioidomycosis
May 20, 2015: Viamet Announces NIH Grant for Compounds Directed at Valley Fever
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Coccidioidomycosis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020


List of Tables


Number of Products under Development for Coccidioidomycosis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Coccidioidomycosis - Pipeline by Acea Biotech Inc, H1 2020
Coccidioidomycosis - Pipeline by Amplyx Pharmaceuticals Inc, H1 2020
Coccidioidomycosis - Pipeline by F2G Ltd, H1 2020
Coccidioidomycosis - Pipeline by Mycovia Pharmaceuticals Inc, H1 2020
Coccidioidomycosis - Pipeline by Scynexis Inc, H1 2020
Coccidioidomycosis - Pipeline by Valley Fever Solutions Inc, H1 2020
Coccidioidomycosis - Dormant Projects, H1 2020